Merck Sharp & Dohme Corp. v. Ben Venue Laboratories Inc.
1:13-cv-01611
π‘ 5G SEP β’ ETSI DeclaredOverview
Parties
Defendant
Ben Venue Laboratories Inc. Operating Company
Represented By
1 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Plaintiff
Millennium Pharmaceuticals Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Merck Sharp & Dohme Corp. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 5,807,825 A Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 36,750,989 A | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 41,802,889 A | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 5,318,899 A | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 54,248,890 A | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,861,193 A | US Continuation / Sibling | View Official Patent → |
Merck Sharp & Dohme Corp. v. APP Pharmaceuticals Inc.
Merck Sharp & Dohme Corp. v. APP Pharmaceuticals Inc.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP β’ ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5807825
Platelet aggregation inhibitors
|
Filed: 1995-06-07
Issued: 1998-09-15
|
Expired (Term Ended)
Expires: 2015-06-07
|
|
|
US5747447
Stable polypeptide composition
|
Filed: 1995-06-05
Issued: 1998-05-05
|
Expired (Term Ended)
Expires: 2015-06-05
|
|
|
US5968902
Platelet aggregation inhibitors
|
Filed: 1995-06-07
Issued: 1999-10-19
|
Expired (Term Ended)
Expires: 2015-06-07
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
2
Dispositive
0
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings